Effects of amoxicillin subinhibitory concentrations on the cross-protection developed by pneumococcal antibodies in mouse sepsis caused by an amoxicillin-resistant serotype 6B Streptococcus pneumoniae strain

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 11, 2004, Pages 4144-4147

  Tarrago D ^a   Aguilar, L ^b   Gimenez M J ^b   Fenoll, A ^a   Casal, J ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b GLAXOSMITHKLINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; HYPERIMMUNE GLOBULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; FEMALE; LOW DRUG DOSE; MORTALITY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SEPSIS; SEROTYPE; STREPTOCOCCUS PNEUMONIAE;

AMOXICILLIN; ANIMALS; ANTIBODIES, BACTERIAL; FEMALE; MICE; MICE, INBRED BALB C; PENICILLIN RESISTANCE; PENICILLINS; SEPSIS; STREPTOCOCCUS PNEUMONIAE; SURVIVAL ANALYSIS;

EID: 7244229691     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.11.4144-4147.2004     Document Type: Article

References (22)

1. Briles, D., E. Ades, J. Paton, J. Sampson, G. Carlone, R. Huebner, E. Virolainen, E. Swiatlo, and S. Hollingshead. 2000. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect. Immun. 68:796-800.
2. Casal, J., L. Aguilar, I. Jado, J. Yuste, M. J. Giménez, J. Prieto, and A. Fenoll. 2002. Effects of specific antibodies against Streptococcus pneumoniae on pharmacodynamic parameters of β-lactams in a mouse sepsis model. Antimicrob. Agents Chemother. 46:1340-1344.
3. Casal, J., M. J. Gimenez, L. Agnilar, J. Yuste, I. Jado, D. Tarrago, and A. Fenoll. 2002. β-Lactam activity against resistant pneumococcal strains is enhanced by the immune system. J. Antimicrob. Chemother. 50(Suppl. S2): 83-86.
4. Casal, J., and D. Tarrago. 2003. Immunity to Streptococcus pneumoniae: factors affecting production and efficacy. Curr. Opin. Infect. Dis. 16:219-224.
5. Cleeland, R., and E. Squires. 1991. Evaluation of new antimicrobials in vitro and in experimental animal infections, p. 739-786. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. Williams & Wilkins, Baltimore, Md.
6. Coughlin, R. T., A. C. White, C. A. Andersen, G. M. Carlone, D. L. Klein, and J. Treanor. 1998. Characterization of pneumococcal specific antibodies in healthy unvaccinated adults. Vaccine 16:1761-1767.
7. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
8. Eliopoulos, G. M., and C. T. Eliopoulos. 1988. Antibiotic combinations: should they be tested? Clin. Microbiol. Rev. 1:139-156.
9. Hostetter, M. K. 2000. Opsonic and nonopsonic interactions of C3 with Streptococcus pneumoniae, p. 309-313. In A. Tomasz (ed.), Streptococcus pneumoniae. Mary Ann Liebert, Inc., New York, N. Y.
10. Jansen, W. T. M., J. Gootges, M. Zelle, D. V. Madare, J. Verhoef, H. Snippe, and A. F. M. Verheul. 1998. Use of highly encapsulated Streptococcus pneumoniae strains in a flow-cytometric assay for assessment of the phagocytic capacity of serotype-specific antibodies. Clin. Diagn. Lab. Immunol. 5:703-710.
11. Kaye, C. M., A. Allen, S. Perry, M. McDonagh, M. Davy, K. Storm, N. Bird, and O. Dewit. 2001. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Clin. Ther. 23:578-584.
12. McCool, T. L., T. R. Cate, E. I. Tuomanen, P. Adrian, T. J. Mitchell, and J. N. Weiser. 2003. Serum immunoglobulin G response to candidate vaccine antigens during experimental human pneumococcal colonization. Infect. Immun. 71:5724-5732.
13. Moellering, R. C., Jr. 2000. Principles of anti-infective therapy, p. 223-235. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 5th ed. Churchill Livingstone, Philadelphia, Pa.
14. National Committee for Clinical Laboratory Standards. 2001. Performance standards for antimicrobial susceptibility testing. Eleventh informational supplement M100-S11. National Committee for Clinical Laboratory Standards, Wayne, Pa.
15. Pallarés, R., F. Gudiol, J. Linares, J. Ariza, G. Rufi, L. Murgui, J. Dorca, and P. F. Viladrich. 1987. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. N. Engl. J. Med. 317:18-22.
16. Pérez-Trallero, E., F. Fernández-Mazarrasa, C. García-Rey, E. Bouza, L. Aguilar, J. Garcia-de-Lomas, F. Baquero, and the Spanish Surveillance Group for Respiratory Pathogens. 2001. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance in Spain. Antimicrob Agents Chemother 45:3334-3340.
17. Renneberg, J. 1993. Definitions of antibacterial interactions in animal infection models. J. Antimicrob. Chemother. 31(Suppl. D):167-175.
18. Saeland, E., H. Jakobsen, G. Ingolfsdottir, S. T. Sigurdardottir, and I. Jonsdottir. 2001. Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B. J. Infect. Dis. 183:253-260.
19. Smith, S. V., and I. M. Gould. 2004. Optimization of antibiotic dosing schedules in the light of increasing antibiotic resistance. Exp. Rev. Antiinfect. Ther. 2:227-234.
20. Wizemann, T., J. Heinrichs, J. Adamou, A. Erwin, C. Kunsch, G. Choi, S. Barash, C. Rosen, H. Masure, E. Tuomanen, A. Gayle, Y. Brewah, W. Walsh, P. Barren, R. Lathigra, M. Hansen, S. Langermann, S. Johnson, and S. Koenig. 2001. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect. Immun. 69:1593-1598.
21. Yuste, J., M. J. Giménez, I. Jado, A. Fenoll, L. Aguilar, and J. Casal. 2001. Enhanced decrease of blood colony counts by specific anti-pneumococcal antibodies in the presence of sub-inhibitory concentrations of amoxicillin. J. Antimicrob Chemother. 48:594-595.
22. Yuste, J., M. J. Giménez, A. Fenoll, L. Aguilar, and J. Casal. 2002. Combined effect of specific antibodies (as serotherapy or preimmunization) and amoxicillin doses in the treatment of Streptococcus pneumoniae sepsis in a mouse model. Antimicrob. Agents Chemother. 46:4043-4044.